Cinda Biotech announced on September 28 that the mid-term analysis of the phase III clinical study (ORIENT-32) for first-line treatment of advanced liver cancer () with Daberxumab® (cindilizumab injection) and Daantong® (bevacizumab antibiotic analogue) reached the main research endpoints of progression-free survival (PFS) and overall survival (OS).

This is the first phase III study in the world announcing combined treatment with a programmed cell death protein 1 (PD-1) inhibitor for first-line treatment of advanced liver cancer that has reached the end of a major study.

Chinese PDThe main battlefields for -1 inhibitors are in the fields of lung cancer, liver cancer, stomach cancer, and rectal cancer.There are four major types of cancer in China: the first is lung cancer (related to smoking, with 800,000 new increases each year), the second is stomach cancer (440,000 new cases are added each year), the third is colorectal cancer (420,000 new years are added each year), and the fourth is liver cancer (related to hepatitis B, hepatitis C, and alcohol consumption, with 400,000 new increases each year).